Glenmede Trust CO Na Editas Medicine, Inc. Transaction History

Glenmede Trust CO Na

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$26.55 - $40.57 $231,303 - $353,445	-8,712 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $342,120 - $635,453	8,712 New	8,712 $357,000
Q1 2021 May 18, 2021	SELL	$39.71 - $90.58 $192,990 - $440,218	-4,860 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $1,001 - $3,120	-37 Reduced 0.76%	4,860 $339,000
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $48,094 - $63,692	1,714 Added 53.85%	4,897 $136,000
Q2 2020 Aug 14, 2020	BUY	$18.5 - $34.34 $23,236 - $43,131	1,256 Added 65.18%	3,183 $92,000
Q4 2019 Feb 12, 2020	SELL	$19.49 - $32.63 $15,942 - $26,691	-818 Reduced 29.8%	1,927 $56,000
Q3 2019 Nov 14, 2019	BUY	$22.49 - $26.81 $12,009 - $14,316	534 Added 24.15%	2,745 $61,000
Q2 2019 Aug 13, 2019	BUY	$20.48 - $27.76 $9,543 - $12,936	466 Added 26.7%	2,211 $54,000
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $222,008 - $387,996	-12,205 Reduced 87.49%	1,745 $39,000
Q3 2018 Nov 15, 2018	SELL	$27.65 - $38.39 $21,981 - $30,520	-795 Reduced 5.39%	13,950 $443,000
Q2 2018 Aug 15, 2018	BUY	$31.4 - $41.01 $305,993 - $399,642	9,745 Added 194.9%	14,745 $529,000
Q4 2017 Feb 15, 2018	BUY	$21.89 - $31.34 $109,450 - $156,700	5,000	5,000 $153,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.